Palomar Medical Technologies, Inc. Receives First FDA Clearance for Fractional Laser Treatment of Striae

Palomar is pleased to announce that the Lux1540™ Fractional non-ablative laser has received the first clearance by the United States Food and Drug Administration (FDA) for the treatment of striae (stretchmarks) using a fractional laser. This new clearance will allow aesthetic practitioners to treat the millions of women in the United States with unwanted stretchmarks by offering long-lasting, superior results.

Ongoing clinical studies have shown that subjects treated with the Lux1540 Fractional non-ablative laser achieved an average improvement of between 51% and 75% in the appearance of their stretchmarks.

This new clearance expands the broad range of treatments offered by the Lux1540, which may be used to treat surgical scars, acne scars, and melasma, as well as offer non-ablative skin resurfacing. This laser is available as a handpiece for Palomar's flagship StarLux® 500 laser and pulsed light platform.

To learn more about the treatment of striae with the Lux1540 Fractional non-ablative laser, download this white paper.